| Factor Information | |
|---|---|
| Data ID | 1276 |
| Factor | reintervention time of valve type |
| Description | The Sorin Mitroflow valve had a shorter time to reintervention than the valve types of CE Magna/MagnaEase (hazard ratios both>7, each P<.001). |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | prognosis and risk assessment |
| Objective | shorter time to reintervention |
| p Value | <0.001 |
| OR | >7.0 |
| Conclusion | Bioprosthetic pulmonary valve replacement in patients with congenital heart disease has excellent short-term outcomes, but children have an approximately 5-fold greater risk of reintervention than adults. Independently of age, reintervention rates vary by valve type. |
| Risk Factor | risk factor |
| CHD Type | |
|---|---|
| ID | 511 |
| CHD Type | isolated CHD |
| CHD Subtype | TOF/CAVC/PS/PA |
| Reference | |
|---|---|
| PMID | 27637422 |
| Year | 2016 |
| Title | Outcome and performance of bioprosthetic pulmonary valve replacement in patients with congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | children and adults | |
| Source | Data | |
| Region | Boston, United States | |
| Method | Kaplan–Meier estimation and Cox proportional hazards regression methodologies | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | surgical bioprosthetic pulmonary valve replacement | |
| Group | Sorin Mitroflow(Treatment) | CE Magna/ Magna Ease(Control) |
| Number | 316 | 223 |
| Age | Age at primary surgery: Mean ± SD =18.6± _x0002_ 12.7; Median (IQR)=16.5 (9.8-22.7) | Age at primary surgery: Mean ± SD =23.4 ± 14.4; Median (IQR) =19.3 (13.3-31.0) |
| Gender (Male: Female) | 182:134 | 142:81 |
| Marker Level | N/A | N/A |
